newsfilter
← Latest News
GlobeNewswire·

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV